stockrow
Friday 6 November 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +13.3%
- Free cash flow
- +2.13%
Quarter to September 2026, against a year earlier
18.44
1.44
+8.47%
Follow RLAY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 4 | — | — |
| (41.12%) | (40.01%) | (36.77%) | (41.16%) | ||
| (37.05%) | (36.39%) | (33.72%) | (37.37%) | ||
ROIC |
(1,508.62%) | (157,022.78%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(49.87%) | (43.29%) | (32.57%) | (36.42%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.37) | (1.19) | (1.05) | (0.98) | |
Free Cash Flow |
(235.86) | (213.36) | (212.20) | (214.02) | |
Capital Expenditures |
(0.41) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(21.03%) | (16.61%) | (11.78%) | (12.83%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,030.61% | 1,406.36% | 2,455.31% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
223.60% | 266.95% | 454.04% | 0.00% | |
Share Based Compensation of Revenue |
246.11% | 292.19% | 438.15% | 0.00% | |
Operating CF/Net income |
0.85 | 0.78 | 0.74 | 0.73 | |
Depreciation/Fixed assets |
0.53 | 0.83 | (1.34) | (2.43) | |
Capex/Depreciation |
(0.45) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.15 | 0.10 | 0.05 | 0.00 | |
Operating CF per Share |
(1.37) | (1.19) | (1.05) | (0.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 6 Nov 2026